

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Acotec Scientific Holdings Limited
先瑞達醫療科技控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6669)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR INDICATION EXPANSION OF
ACOART ORCHID® & DHALIA™
BY PRC NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that on July 7, 2022, the Company received the updated registration certificate from the PRC National Medical Products Administration for the indication expansion of AcoArt Orchid® & Dhalia™ for treating Arteriovenous Fistula (“**AVF**”) stenosis.

The Company initiated an randomized controlled clinical trial for the AcoArt Orchid® & Dhalia™ indicated for treating AVF stenosis in China to evaluate its safety and efficacy in May 2018 and have completed the six-month follow-ups and the twelve-month follow-ups for all the trial subjects. According to the six-month follow-ups statistics, patency rate of drug-coated balloons (“**DCB**”) group is 91.4%, as compared to the 66.9% patency rate for percutaneous transluminal angioplasty (“**PTA**”) group. According to the twelve-month follow-ups statistics, patency rate of DCB group is 66.1%, as compared to the 46.4% patency rate for PTA group .

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET ACOART ORCHID® & DHALIA™ FOR TREATING AVF STENOSIS SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By Order of the Board
Acotec Scientific Holdings Limited
Jing LI
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, July 13, 2022

As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Ke TANG and Mr. Chen CHEN, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.